Ribosome-targeted and Adjuvant Strategies to Combat Antibiotic Resistance

This study examines ribosome-targeted and adjuvant strategies to combat the growing threat of antimicrobial resistance (AMR), with a focus on novel therapeutic approaches, including phage therapy, monoclonal antibodies, CRISPR systems, and AI-driven drug discovery. The objective is to review current challenges and evaluate innovative strategies targeting bacterial ribosomes, a primary site for antibiotic action.

A systematic literature review was conducted using databases, such as PubMed, ScienceDirect, Scopus, and Google Scholar.

The study indicates that bacteria evade ribosome-targeting antibiotics through various mechanisms, including porin modification, efflux pumps, ribosomal mutations, and enzymatic degradation. Innovative strategies, including AI-enabled virtual screening, phage-antibiotic synergy, ribosomal protein-targeted monoclonal antibodies and vaccines, and CRISPR-Cas systems, have shown potential in overcoming these mechanisms and restoring antibiotic efficacy.

These advanced strategies represent a significant shift from traditional approaches, as they directly target ribosomal functions or resistance genes. While promising, limitations such as phage specificity, challenges in CRISPR delivery, and regulatory concerns must be addressed to ensure clinical translation. The integration of AI with molecular techniques enhances therapeutic precision and development speed.

Ribosome-targeted therapies and adjunctive strategies, such as AI, phage therapy, monoclonal antibodies, and CRISPR, offer precise and innovative solutions to overcome antibiotic resistance.